Catalent has over 80 years of softgel manufacturing experience, and continues to deliver innovation with technological enhancements, such as chewable softgels and coatings, and formulations to enable modified-release for Rx, OTC and consumer health products.
OptiGel™ Bio is a lipid based softgel technology that enables macromolecules to be delivered orally and overcome permeability and stability challenges in a more easily administered form than intravenous injection. Enteric coatings enable targeted delivery of drugs and can limit degradation of the API in the stomach.
The award-winning OptiShell™ platform enhances both drug therapeutic performance and patient experience. The technology allows for high-temperature encapsulation of semi-solid fill material within a non-gelatin, plant-based shell, and is ideal for the encapsulation of higher melting-point fill formulations, and the production of soft capsules containing semi-solid matrices for modified-release of poorly soluble and/or poorly permeable drug compounds.
Contact Details :
Catalent Pharma Solutions
Website: www.catalent.com
E-mail: solutions@catalent.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.